Latest in Drug Developers Went
Sort by
388 items
-
Viking Therapeutics’ stock soars 18% as data on oral weight-loss drug looms
Viking Therapeutics Inc.’s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings ...Business - MarketWatch - October 24 -
Olympus shares drop over 5% after CEO resigns over drug allegation
The stock slid 5.3% on the Tokyo Stock Exchange following news of Stefan Kaufmann's resignation.Business - CNBC - October 28 -
‘People didn’t believe Africa could be a source of innovation’: how the continent holds the key to future drug research
Prof Kelly Chibale says the world is failing to take advantage of African genetic diversity, and everyone could be losing out. Africa has the greatest variety in human genes anywhere on the planet ...World - The Guardian - October 28 -
How can we help stop deadly drug-resistant infections spreading? Debt relief | Glenda Gray
Millions of lives could be saved if the world would only consider more innovative ways to help poorer nations tackle AMR. Drug-resistant infection, already one of the world’s biggest killers, is ...World - The Guardian - October 29 -
Dozens jailed in drug smuggling mega-trial: "Your honor, I played, I lost."
The multinational cocaine and cannabis trafficking enterprise was busted after investigators cracked encrypted messaging apps.Top stories - CBS News - October 29 -
Anti-aging enthusiasts are turning to the drug rapamycin to help extend their lives—can it work? A longevity doctor weighs in
Longevity seekers are taking rapamycin in hopes of living longer. Here's what a health and longevity doctor has to say about the drug.Business - CNBC - October 29 -
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company's multiple sclerosis products.Business - CNBC - October 30 -
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase manufacturing capacity.Business - CNBC - October 30